ZIOPHARM Oncology (ZIOP) said in a statement earlier today that the recent patient death from intracranial hemorrhage in its Phase 1 clinical trial evaluating Ad-RTS-hIL-12 + orally administered veledimex in progressive glioblastoma or grade III malignant glioma was determined to be unrelated to the study drug. The company said that enrollment in the study remains open and longer-term survival data will be released later this year.ZIOP shares initially rose sharply on the news but have given up their gains since. At last check, the stock was down 1.6%.